NanoBio Completes Phase 2b Study In Herpes Labialis
ANN ARBOR - NanoBio Corporation reported top-level findings Monday from its phase 2b study of NB-001, a topical lotion to treat herpes labialis (cold sores). The randomized, double-blind, vehicle- controlled study met its primary and secondary endpoints by demonstrating clear efficacy and safety in 482 patients. NanoBio's lotion resulted in faster healing of cold sores,